维普中文期刊产品整合服务
32篇 您的检索式:作者名="JAMES NH"
    题名 作者 年代 出处 被引量
1Phase III randomized comparison of gemcitabine and carboplatin(GC) with mitomycin,ifosfamide and cisplatin (MIP) in advanced non - small cell lung cancer( NSCLC ) 显示文摘Rudd RM Gower NH James LE 2002Proc Am Soc Clin Oncol2002,21,:1
2Vascular endothelialgrowth factor receptors VEGFR-2and VEGFR-3are lo-calized primarily to the vasculature in human primary solidcancers显示文摘Smith NR Baker D James NH 2010Clin Cancer Res2010,16,14:1
3Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer显示文摘BRAVE SR ODEDRA R JAMES NH 2011Int J Oncol2011,39,1:1
4Vandetanib inhibits both VEGFR -2 and EGFR signalling at clinically relevant drug levels in prcelinical models of human cancer显示文摘Brave SR Odedra R James NH 2011International journal of oneology2011,39,1:1
5Evidence for the suppression of apoptosis by the peroxisome proliferator activated-receptor alpha (PPAR alpha)显示文摘 James NH Woodyatt NJ 1998Carcinogenesis1998,19,:1
6Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinieal models of human Caneer显示文摘Brave SR Odedra R James NH 2011Int J Oncol2011,39,27:1
7Tumor necrosis factor alpha (TNF alpha) suppress apoptosis and induces DNA synthesis in rodent hepatocytes: a mediator of the hepatocarcinogenicity of peroxisome proliferators显示文摘Rolfe M James NH Roberts RA 0,,:1
8Evidence for the suppression of apoptosis by the peroxisome proliferator activated - receptor alpha ( PPAR alpha) 显示文摘Roberts RA James NH Woodyatt NJ 1998Carcinogenesis1998,,1:1
9Phase Ⅲ randomized comparison of gemcitabine and carboplatin(GC) with mitomycin,ifosfamide and cisplatin(MIP)in advanced non-small cell lung cancer(NSCLC) 显示文摘Rudd RM Gower NH James LE 2002Proc Am Soc Clin Oncol2002,20,:1
10Peroxisome proliferators-activated receptor (PPAR) alpha-regulated growth responses and their importance to hepatocarcinogenesis显示文摘James NH Gill JH Brindle R 1998Toxicology Letters1998,,12:1
11Altered bcl-2 family expression during non-genototic hepatocarcinogenesis in mice显示文摘James GC Elizabeth HR Laura NH 1999Carcinogenesis1999,20,8:1
12Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers 显示文摘Smith NR Baker D James NH 2010Clin Cancer Res2010,16,14:1
13Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers 显示文摘Smith NR Baker D James NH 2010Clin Cancer Res2010,16,14:1
14Bilateral metastatic hemangiopericytoma ten years after primary intracranial lesion 显示文摘LEE NH KRISTOPHER W JAMES MM 2006Int BrazJ Urol2006,32,1:1
15Suppression of mouse hepatocyte apoptosis by peroxisome proliferators: role of PPARalpha and TNFalpha显示文摘Hasmall SC James NH Macdonald N Gonzalez FJ Peters JM Roberts RA 2000Mutat Res2000,448,2:1
16Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers 显示文摘Smith NR Baker D James NH 2010Clin Cancer Res2010,16,14:1
17Tumour necrosis factor alpha (TNF alpha) suppresses apoptosis and induces DNA synthesis in rodent hepatocytes: a mediator of the hepatocarcinogenicity of peroxisome proliferators?显示文摘Rolfe M James NH Roberts RA 1997Carcinogenesis1997,18,11:1
18Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers 显示文摘Smith NR Baker D James NH 2010Clin Cancer Res2010,16,14:1
19Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers 显示文摘Smith NR Baker D James NH 2010Clin Cancer Res2010,16,14:1
20Apoptosis and proliferation in nongenotoxic carcinogenesis: species differences and role of PPARalpha显示文摘Roberts RA James NH Hasmall SC Holden PR Lambe K Macdonald N 2000Toxicol Lett2000,,:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费